Increased mitochondrial mass in mitochondrial myopathy mice
- Anna Wredenberg*,
- Rolf Wibom†,
- Hans Wilhelmsson*,
- Caroline Graff*,
- Heidi H. Wiener‡,
- Steven J. Burden‡,
- Anders Oldfors§,
- Håkan Westerblad¶, and
- Nils-Göran Larsson*,∥
- Departments of *Medical Nutrition and Biosciences and† Medical Laboratory Sciences and Technology, Karolinska Institute, Huddinge Hospital, S-141 86 Huddinge, Sweden;§ Department of Pathology, Sahlgrenska Hospital, S-413 45 Göteborg, Sweden; ‡Skirball Institute for Molecular Medicine, New York University Medical Center, NY 10016; and ¶Department of Physiology and Pharmacology, Karolinska Institute, S-171 77 Stockholm, Sweden
-
Communicated by Rolf Luft, Karolinska Hospital, Stockholm, Sweden (received for review June 24, 2002)
Abstract
We have generated an animal model for mitochondrial myopathy by disrupting the gene for mitochondrial transcription factor A (Tfam) in skeletal muscle of the mouse. The knockout animals developed a myopathy with ragged-red muscle fibers, accumulation of abnormally appearing mitochondria, and progressively deteriorating respiratory chain function in skeletal muscle. Enzyme histochemistry, electron micrographs, and citrate synthase activity revealed a substantial increase in mitochondrial mass in skeletal muscle of the myopathy mice. Biochemical assays demonstrated that the increased mitochondrial mass partly compensated for the reduced function of the respiratory chain by maintaining overall ATP production in skeletal muscle. The increased mitochondrial mass thus was induced by the respiratory chain deficiency and may be beneficial by improving the energy homeostasis in the affected tissue. Surprisingly, in vitro experiments to assess muscle function demonstrated that fatigue development did not occur more rapidly in myopathy mice, suggesting that overall ATP production is sufficient. However, there were lower absolute muscle forces in the myopathy mice, especially at low stimulation frequencies. This reduction in muscle force is likely caused by deficient formation of force-generating actin–myosin cross bridges and/or disregulation of Ca2+ homeostasis. Thus, both biochemical measurements of ATP-production rate and in vitro physiological studies suggest that reduced mitochondrial ATP production might not be as critical for the pathophysiology of mitochondrial myopathy as thought previously.
Footnotes
-
↵ ∥ To whom correspondence should be addressed. E-mail: nils-goran.larsson{at}mednut.ki.se.
- Abbreviations:
-
Tfam, mitochondrial transcription factor A
-
RRF, ragged-red muscle fiber
-
Mlc, myosin light chain
-
COX, cytochrome c oxidase
-
SDH, succinate dehydrogenase
-
SCR, succinate:cytochrome c reductase
-
CS, citrate synthase
-
MAPR, mitochondrial ATP-production rate
-
EDL, extensor digitorum longus
-
- Copyright © 2002, The National Academy of Sciences
.gif?ad=15653&adview=true)





